<unk>  is primarily used in patients with systemic lupus erythematosus. When it was introduced in 2011, it was the first new drug approved to treat lupus in 56 years. Sales rose to $31.2 million in the first quarter of 2012. Clinical trials found<unk>  to be safe in treating SLE, but the magnitude of benefit was small, and Phase III trials excluded the most severe cases of SLE, involving kidney and brain damage. Reviewers at the United States Food and Drug Administration (FDA) expressed concern that the drug was only "marginally" effective, and that there were more deaths in the treatment group. Defenders said that in addition to its modest efficiency,<unk>  allowed patients to significantly reduce their use of corticosteroids.<unk>  was not effective in Phase II clinical trials for rheumatoid arthritis. It was moderately effective in Phase II trials for Sjögren syndrome. In December 2020<unk>  was approved by the FDA as a treatment for lupus nephritis in combination with standard treatment.
Belimumab
Sarilumab
Golimumab
Burosumab
Belatacept
Tofacitinib
Avelumab
Anifrolumab